Top Markets
Coin of the day
Rapid Therapeutic Science Laboratories, Inc. Rapid Therapeutic Science Laboratories, Inc.

Rapid Therapeutic Science Laboratories, Inc.

RTSL
Rangering i aksjer #42555
Rapid Therapeutic Science Laboratories, Inc. (RTSL) is a biotechnology firm... Rapid Therapeutic Science Laboratories, Inc. (RTSL) is a biotechnology firm specializing in the aerosolized delivery of non-psychoactive cannabinoids directly into the bloodstream. This innovative approach is aimed at treating various conditions, including chronic pain, post-traumatic stress disorder (PTSD), insomnia, and aiding in surgery recovery, among other health issues. RTSL's product portfolio features pressurized meter dose inhalers (MDIs), designed to precisely dispense an aerosolized mist into the lungs, alongside sublingual oral spray devices. Furthermore, the company offers water-soluble cannabidiol (CBD) and cannabigerol (CBG) isolates under its "nhaler" brand. Established in 2013 and based in Dallas, Texas, the company adopted its current name, Rapid Therapeutic Science Laboratories, Inc., in January 2020, having previously operated as Holly Brothers Pictures, Inc. It was also formerly a subsidiary of Texas Mdi, Inc.
Aksjekurs
$0.0001
Sist synkronisert: 2026-08-11
Markedsverdi
$883.00
Endring (1 dag)
0.00%
Endring (1 år)
-96.67%
Land
US
Handel Rapid Therapeutic Science Laboratories, Inc. (RTSL)

Kategori

Inntekter for Rapid Therapeutic Science Laboratories, Inc. (RTSL)
Inntekter i 2026 TTM: 0
Ifølge Rapid Therapeutic Science Laboratories, Inc. sine nyeste økonomiske rapporter er selskapets nåværende resultat 0. I 2026 hadde selskapet et resultat på 0, lik resultatet i 2026, som var 0. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for Rapid Therapeutic Science Laboratories, Inc. fra 2026 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
Ikke nok data for de angitte datoene.
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
$7.51B -
US
$5.15B -
US
$5.56B -
IE
$3.86B -
US
$1.42B -
US